Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07593053

Phase I Prognostic Online (PIPO) Tool

Sponsor: Vall d'Hebron Institute of Oncology

View on ClinicalTrials.gov

Summary

Clinical trials are studies that test new treatments to see if they work and are safe for people with certain illnesses. Phase I clinical trials are the earliest stage of testing, where researchers give a new treatment to a small group of people to see if it's safe and how much of it can be given before causing harmful side effects. Selecting patients for these trials is challenging, especially since most of them have already tried other treatments that didn't work. To make sure patients are not harmed during the trial, researchers need to estimate how long they might live, so they don't give the new treatment to someone who might not live long enough to see if it works. Doctors use a variety of tools to estimate how long a patient might live, but it's not always easy to do. To help with this, researchers have developed a new tool called the Phase I prognostic online (PIPO) tool. It helps estimate how long a patient might live by looking at different factors like age, the type of cancer, and other medical conditions. This tool can help doctors decide if a patient should be included in a clinical trial or not. The researchers plan to test this tool to see how well it works, with the goal of using it in clinical practice to help doctors estimate life expectancy and select patients for clinical trials. This will make it easier for doctors to help their patients get access to new treatments that might help them.

Official title: Phase I Prognostic Online (PIPO) Tool: a New Aid to Improve Patient Selection for Early Phase Clinical Trials

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

586

Start Date

2023-02-02

Completion Date

2026-04-30

Last Updated

2026-05-22

Healthy Volunteers

No

Conditions

Interventions

DRUG

Immune checkpoint inhibitor, targeted agents

Immune checkpoint inhibitor, targeted agents

Locations (1)

Vall d'Hebron Institue of Oncology

Barcelona, Spain